Squamocin modulates histone H3 phosphorylation levels and induces G1 phase arrest and apoptosis in cancer cells

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Lee, Chien Chih ^a   Lin, Yi Hsiung ^a   Chang, Wen Hsin ^b   Lin, Pei Chin ^c   Wu, Yang Chang ^a,d,e   Chang, Jan Gowth ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA B KINASE; HISTONE H3; MESSENGER RNA; SQUAMOCIN; STRESS ACTIVATED PROTEIN KINASE 1; ANTINEOPLASTIC AGENT; CYTOTOXIN; FURAN DERIVATIVE; HISTONE; LACTONE; PROTAMINE KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; INCUBATION TIME; INHIBITION KINETICS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOLOGICAL MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; METABOLISM; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FURANS; G1 PHASE; HISTONES; HUMANS; LACTONES; MODELS, BIOLOGICAL; NEOPLASMS; PHOSPHORYLATION; PROTAMINE KINASE;

EID: 79551688962     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-58     Document Type: Article

References (51)

1. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128(4):693-705. 10.1016/j.cell.2007.02.005, 17320507.
2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-428.
3. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007, 128(4):683-692. 10.1016/j.cell.2007.01.029, 17320506.
4. Hake SB, Xiao A, Allis CD. Linking the epigenetic 'language' of covalent histone modifications to cancer. Br J Cancer 2007, 96(Suppl):R31-39.
5. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009, 174(5):1619-1628. 10.2353/ajpath.2009.080874, 2671251, 19349354.
6. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000, 403(6765):41-45. 10.1038/47412, 10638745.
7. Perez-Cadahia B, Drobic B, Davie JR. H3 phosphorylation: dual role in mitosis and interphase. Biochem Cell Biol 2009, 87(5):695-709. 10.1139/O09-053, 19898522.
8. Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol 2004, 14(14):R546-551. 10.1016/j.cub.2004.07.007, 15268870.
9. Prigent C, Dimitrov S. Phosphorylation of serine 10 in histone H3, what for?. J Cell Sci 2003, 116(Pt 18):3677-3685. 10.1242/jcs.00735, 12917355.
10. Graber MW, Schweinfest CW, Reed CE, Papas TS, Baron PL. Isolation of differentially expressed genes in carcinoma of the esophagus. Ann Surg Oncol 1996, 3(2):192-197. 10.1007/BF02305800, 8646521.
11. Chadee DN, Hendzel MJ, Tylipski CP, Allis CD, Bazett-Jones DP, Wright JA, Davie JR. Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts. J Biol Chem 1999, 274(35):24914-24920. 10.1074/jbc.274.35.24914, 10455166.
12. Choi HS, Choi BY, Cho YY, Mizuno H, Kang BS, Bode AM, Dong Z. Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. Cancer Res 2005, 65(13):5818-5827. 10.1158/0008-5472.CAN-05-0197, 2227263, 15994958.
13. Kim HG, Lee KW, Cho YY, Kang NJ, Oh SM, Bode AM, Dong Z. Mitogen- and stress-activated kinase 1-mediated histone H3 phosphorylation is crucial for cell transformation. Cancer Res 2008, 68(7):2538-2547. 10.1158/0008-5472.CAN-07-6597, 2288657, 18381464.
14. Espino PS, Pritchard S, Heng HH, Davie JR. Genomic instability and histone H3 phosphorylation induction by the Ras-mitogen activated protein kinase pathway in pancreatic cancer cells. Int J Cancer 2009, 124(3):562-567. 10.1002/ijc.23959, 19004007.
15. Adams RR, Maiato H, Earnshaw WC, Carmena M. Essential roles of Drosophila inner centromere protein (INCENP) and aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation. J Cell Biol 2001, 153(4):865-880. 10.1083/jcb.153.4.865, 2192373, 11352945.
16. Chen CY, Chang FR, Chiu HF, Wu MJ, Wu YC. Aromin-A, an Annonaceous acetogenin from Annona cherimola. Phytochemistry 1999, 51(3):429-433. 10.1016/S0031-9422(99)00002-3, 10382318.
17. Chan CH, Ko CC, Chang JG, Chen SF, Wu MS, Lin JT, Chow LP. Subcellular and functional proteomic analysis of the cellular responses induced by Helicobacter pylori. Mol Cell Proteomics 2006, 5(4):702-713.
18. Andreassi C, Angelozzi C, Tiziano FD, Vitali T, De Vincenzi E, Boninsegna A, Villanova M, Bertini E, Pini A, Neri G, et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004, 12(1):59-65. 10.1038/sj.ejhg.5201102, 14560316.
19. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010, 1802(4):396-405.
20. Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008, 22(4):954-965. 10.1096/fj.06-7859rev, 18039929.
21. Liu CJ, Lo JF, Kuo CH, Chu CH, Chen LM, Tsai FJ, Tsai CH, Tzang BS, Kuo WW, Huang CY. Akt mediates 17beta-estradiol and/or estrogen receptor-alpha inhibition of LPS-induced tumor necresis factor-alpha expression and myocardial cell apoptosis by suppressing the JNK1/2-NFkappaB pathway. J Cell Mol Med 2009, 13(9B):3655-3667. 10.1111/j.1582-4934.2009.00669.x, 20196785.
22. Caparros-Lefebvre D, Steele J, Kotake Y, Ohta S. Geographic isolates of atypical Parkinsonism and tauopathy in the tropics: possible synergy of neurotoxins. Mov Disord 2006, 21(10):1769-1771. 10.1002/mds.21024, 16874753.
23. Kotake Y, Okuda K, Kamizono M, Matsumoto N, Tanahashi T, Hara H, Caparros-Lefebvre D, Ohta S. Detection and determination of reticuline and N-methylcoculaurine in the Annonaceae family using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 806(1):75-78. 10.1016/j.jchromb.2004.03.017, 15149614.
24. Alali FQ, Liu XX, McLaughlin JL. Annonaceous acetogenins: recent progress. J Nat Prod 1999, 62(3):504-540. 10.1021/np980406d, 10096871.
25. Bermejo A, Figadere B, Zafra-Polo MC, Barrachina I, Estornell E, Cortes D. Acetogenins from Annonaceae: recent progress in isolation, synthesis and mechanisms of action. Nat Prod Rep 2005, 22(2):269-303. 10.1039/b500186m, 15806200.
26. Kojima N, Tanaka T. Medicinal chemistry of Annonaceous acetogenins: design, synthesis, and biological evaluation of novel analogues. Molecules 2009, 14(9):3621-3661. 10.3390/molecules14093621, 19783948.
27. Derbre S, Roue G, Poupon E, Susin SA, Hocquemiller R. Annonaceous acetogenins: the hydroxyl groups and THF rings are crucial structural elements for targeting the mitochondria, demonstration with the synthesis of fluorescent squamocin analogues. Chembiochem 2005, 6(6):979-982. 10.1002/cbic.200400396, 15861433.
28. Derbre S, Gil S, Taverna M, Boursier C, Nicolas V, Demey-Thomas E, Vinh J, Susin SA, Hocquemiller R, Poupon E. Highly cytotoxic and neurotoxic acetogenins of the Annonaceae: new putative biological targets of squamocin detected by activity-based protein profiling. Bioorg Med Chem Lett 2008, 18(21):5741-5744. 10.1016/j.bmcl.2008.09.091, 18851912.
29. Liaw CC, Wu TY, Chang FR, Wu YC. Historic Perspectives on Annonaceous Acetogenins from the Chemical Bench to Preclinical Trials. Planta Med 2010, 76(13):1390-404. 10.1055/s-0030-1250006, 20577943.
30. Philchenkov A. Caspases: potential targets for regulating cell death. J Cell Mol Med 2004, 8(4):432-444. 10.1111/j.1582-4934.2004.tb00468.x, 15601572.
31. Duval RA, Poupon E, Romero V, Peris E, Lewin G, Cortes D, Brandt U, Hocquemiller R. Analogues of cytotoxic squamocin using reliable reactions: new insights into the reactivity and role of the α,β-unsaturated lactone of the annonaceous acetogenins. Tetrahedron 2006, 62(26):6258-6257.
32. Duval RA, Poupon E, Brandt U, Hocquemiller R. Remarkable substituent effect: beta-aminosquamocin, a potent dual inhibitor of mitochondrial complexes I and III. Biochim Biophys Acta 2005, 1709(3):191-194. 10.1016/j.bbabio.2005.07.011, 16139789.
33. Derbre S, Duval R, Roue G, Garofano A, Poupon E, Brandt U, Susin SA, Hocquemiller R. Semisynthesis and screening of a small library of pro-apoptotic squamocin analogues: selection and study of a benzoquinone hybrid with an improved biological profile. ChemMedChem 2006, 1(1):118-129. 10.1002/cmdc.200500011, 16892343.
34. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26(22):3279-3290. 10.1038/sj.onc.1210421, 17496922.
35. Monick MM, Powers LS, Barrett CW, Hinde S, Ashare A, Groskreutz DJ, Nyunoya T, Coleman M, Spitz DR, Hunninghake GW. Constitutive ERK MAPK activity regulates macrophage ATP production and mitochondrial integrity. J Immunol 2008, 180(11):7485-7496. 2410094, 18490749.
36. Roy SK, Srivastava RK, Shankar S. Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 2010, 5:10. 10.1186/1750-2187-5-10, 2915986, 20642839.
37. Nishioka C, Ikezoe T, Yang J, Yokoyama A. Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells. Apoptosis 2009, 14(9):1108-1120. 10.1007/s10495-009-0372-4, 19548087.
38. Thomson S, Clayton AL, Hazzalin CA, Rose S, Barratt MJ, Mahadevan LC. The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO J 1999, 18(17):4779-4793. 10.1093/emboj/18.17.4779, 1171550, 10469656.
39. Dyson MH, Thomson S, Inagaki M, Goto H, Arthur SJ, Nightingale K, Iborra FJ, Mahadevan LC. MAP kinase-mediated phosphorylation of distinct pools of histone H3 at S10 or S28 via mitogen- and stress-activated kinase 1/2. J Cell Sci 2005, 118(Pt 10):2247-2259. 10.1242/jcs.02373, 15870105.
40. Yeung SC, Gully C, Lee MH. Aurora-B kinase inhibitors for cancer chemotherapy. Mini Rev Med Chem 2008, 8(14):1514-1525. 10.2174/138955708786786480, 19075809.
41. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003, 22(4):451-464. 10.1023/A:1023789416385, 12884918.
42. Mahadevan LC, Willis AC, Barratt MJ. Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors. Cell 1991, 65(5):775-783. 10.1016/0092-8674(91)90385-C, 2040014.
43. Lee YJ, Shukla SD. Histone H3 phosphorylation at serine 10 and serine 28 is mediated by p38 MAPK in rat hepatocytes exposed to ethanol and acetaldehyde. Eur J Pharmacol 2007, 573(1-3):29-38. 10.1016/j.ejphar.2007.06.049, 2723821, 17643407.
44. Juan G, Traganos F, James WM, Ray JM, Roberge M, Sauve DM, Anderson H, Darzynkiewicz Z. Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry 1998, 32(2):71-77. 10.1002/(SICI)1097-0320(19980601)32:2<71::AID-CYTO1>3.0.CO;2-H, 9627219.
45. Goto H, Yasui Y, Nigg EA, Inagaki M. Aurora-B phosphorylates Histone H3 at serine28 with regard to the mitotic chromosome condensation. Genes Cells 2002, 7(1):11-17. 10.1046/j.1356-9597.2001.00498.x, 11856369.
46. Degli Esposti M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim Biophys Acta 1998, 1364(2):222-235. 10.1016/S0005-2728(98)00029-2, 9593904.
47. Kwak HB, Lee BK, Oh J, Yeon JT, Choi SW, Cho HJ, Lee MS, Kim JJ, Bae JM, Kim SH, et al. Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression. Bone 2010, 46(3):724-731. 10.1016/j.bone.2009.10.042, 19900598.
48. Deng YT, Huang HC, Lin JK. Rotenone induces apoptosis in MCF-7 human breast cancer cell-mediated ROS through JNK and p38 signaling. Mol Carcinog 2010, 49(2):141-151.
49. Hoglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duyckaerts C, Feger J, Champy P, Prigent A, Medja F, Lombes A, et al. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 2005, 95(4):930-939. 10.1111/j.1471-4159.2005.03493.x, 16219024.
50. Lyamzaev KG, Izyumov DS, Avetisyan AV, Yang F, Pletjushkina OY, Chernyak BV. Inhibition of mitochondrial bioenergetics: the effects on structure of mitochondria in the cell and on apoptosis. Acta Biochim Pol 2004, 51(2):553-562.
51. Bai J, Nakamura H, Ueda S, Kwon YW, Tanaka T, Ban S, Yodoi J. Proteasome-dependent degradation of cyclin D1 in 1-methyl-4-phenylpyridinium ion (MPP+)-induced cell cycle arrest. J Biol Chem 2004, 279(37):38710-38714. 10.1074/jbc.M403329200, 15247282.